INTENSITY THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
INTENSITY THERAPEUTICS, INC. (INTS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-27
- INTENSITY THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.50%.
- INTENSITY THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.70%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | -0.50% 10-K · filed 2026-03-27 |
| 2024-12-31 | -0.70% 10-K · filed 2026-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |